Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

684 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-09-27

Study Completion Date

2020-12-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Research Questions:

To understand the clinical outcomes of patients treated with sunitinib in first line and axitinib in second line in a real world setting as therapies for metastatic and/or advanced renal cell carcinoma (mRCC).

Primary Objective:

1. What is the progression free survival (PFS) of patients treated in first line with sunitinib, and stratified by Memorial Sloan-Kettering Cancer Center / International Metastatic Renal Cell Carcinoma Database Consortium (MSKCC/IMDC) risk category (favourable, intermediate, poor)?
2. What is the progression free survival (PFS) of patients treated in second line with axitinib, and stratified by MSKCC/IMDC risk category (favourable, intermediate, poor)?

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib

NCT03592199

Clear Cell Renal Cell Carcinoma

UNKNOWN PHASE2

Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule

NCT01499121

Clear Cell, Metastatic Renal Cell Carcinoma

COMPLETED PHASE2

Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy

NCT00663559

Carcinoma Renal Cells

COMPLETED PHASE2

Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)

NCT02853331

Renal Cell Carcinoma

ACTIVE_NOT_RECRUITING PHASE3

An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK

NCT05394493

Advanced Renal Cell Carcinoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Research Questions:

To understand the clinical outcomes of patients treated with sunitinib in first line and axitinib in second line in a real world setting as therapies for metastatic and/or advanced renal cell carcinoma (mRCC).

Primary Objective:

1. What is the progression free survival (PFS) of patients treated in first line with sunitinib, and stratified by Memorial Sloan-Kettering Cancer Center / International Metastatic Renal Cell Carcinoma Database Consortium (MSKCC/IMDC) risk category (favourable, intermediate, poor)?
2. What is the progression free survival (PFS) of patients treated in second line with axitinib, and stratified by MSKCC/IMDC risk category (favourable, intermediate, poor)?

Secondary Objectives:

First Line:

1. What is the overall survival (OS) of all patients in first line with sunitinib, and stratified by MSKCC risk (favourable, intermediate, poor)?
2. What is the duration of therapy with sunitinib in first line (using time to treatment discontinuation \[TTD\]) for all patients and stratified by MSKCC risk (favourable, intermediate, poor)
3. Objective response rate (ORR)
4. Duration of objective response (complete response \[CR\] or partial response \[PR\])
5. Examine factors that predict TTD, e.g. risk stratification, or individual/grouped parameters that comprise the prognostic classification systems

1. Less than one year from time of diagnosis
2. Karnovsky performance status less than 80%
3. Haemoglobin less than the lower limit of normal (e.g. less than 12 g/dl)
4. Serum calcium great than the upper limit of normal (e.g. 10 mg/dl or : 2.5 mmol/l)
5. Neutrophil greater than the upper limit of normal (e.g. greater than 7.0 x109 dl)
6. Platelets greater than the upper limit of normal (e.g. greater than 400 000)
7. Lactate dehydrogenase greater than 1.5 times the upper limit of normal
8. Fuhrmann grade of tumour
9. Tumour subtype e.g. clear cell versus. non-clear cell
6. Safety and tolerability data reporting for first line sunitinib

Second line:

1. What is the OS of all patients in second line with axitinib, and stratified by MSKCC risk (favourable, intermediate, poor)?
2. What is the duration of therapy with axitinib in second line (using TTD) for all patients and stratified by MSKCC risk (favourable, intermediate, poor)
3. ORR
4. Duration of objective response (CR or PR)
5. Examine factors that predict duration of TTD, e.g. risk stratification, or individual/grouped parameters that comprise the prognostic classification systems

1. Less than one year from time of diagnosis
2. Karnovsky performance status less than 80%
3. Haemoglobin less than the lower limit of normal (e.g. less than 12 g/dl)
4. Serum calcium great than the upper limit of normal (e.g. 10 mg/dl or : 2.5 mmol/l)
5. Neutrophil greater than the upper limit of normal (e.g. greater than 7.0 x109 dl)
6. Platelets greater than the upper limit of normal (e.g. greater than 400 000)
7. Lactate dehydrogenase greater than 1.5 times the upper limit of normal
8. Fuhrmann grade of tumour
9. Tumour subtype e.g. clear cell vs. non-clear cell
6. Safety and tolerability reporting for second line axitinib

The objectives listed below will also be assessed as exploratory analyses for various patient subgroups of interest, and will be conducted if sufficient numbers of patients are available:

1. Axitinib PFS and OS, as a second line therapy following sunitinib, pazopanib, or following other Tyrosine kinase inhibitors (e.g. sorafenib)
2. Axitinib PFS and OS as a third line therapy
3. Axitinib PFS and OS post-immunotherapy (IO), taking into consideration 2nd and 3rd therapy lines, following all IO therapy options, E.g. atezolizumab/bevacizumab, nivolumab/ipilumimab, nivolumab, interleukin-2
4. For the post-sunitinib axitinib cohort: What was the duration of sunitinib therapy before patients transitioned to axitinib?
5. For the post-pazopanib axitinib cohort: What was the duration of sunitinib therapy before patients transitioned to axitinib?
6. Is the duration of therapy on first line sunitinib and/or pazopanib related to duration of therapy for second line axitinib?

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma Renal Cell

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with advanced RCC

Patients with a diagnosis of kidney cancer (renal cell carcinoma, advanced or metastatic)

Sunitinib

Intervention Type DRUG

Tyrosine kinase inhibitor, licensed for use in treatment of renal cell carcinoma.

Axitinib

Intervention Type DRUG

Tyrosine kinase inhibitor, licensed for use in treatment of renal cell carcinoma.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sunitinib

Tyrosine kinase inhibitor, licensed for use in treatment of renal cell carcinoma.

Intervention Type DRUG

Axitinib

Tyrosine kinase inhibitor, licensed for use in treatment of renal cell carcinoma.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sutent Inlyta

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Over the age of 18 years
2. Diagnosis of renal cell carcinoma
3. Treatment with sunitinib and/or axitinib
4. Timeframe: from database inception date (2002) until June 30, 2018.

Exclusion Criteria

Patients meeting any of the following criteria will not be included in the study:

1. Under the age of 18 years
2. Diagnosis other than renal cell carcinoma
3. No treatment with sunitinib and/or axitinib

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No